Aurobindo Pharma Ltd

₹ 411 -0.48%
02 Feb 12:53 p.m.
aurobindo.com BSE: 524804 NSE : AUROPHARMA
About

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)

Key Points

Leading Pharmaceutical company [1]
Aurobindo Pharma is India’s second-largest pharma company & Largest generics company in the US (by Rx dispensed). It is also the largest generic company in the US and is amongst the top 10 generic companies in seven out of 11 countries in Europe.[2]The Company is among the top 5 listed pharmaceutical companies in India by FY22 revenues [3]

Website BSE NSE
  • Market Cap ₹ 24,065 Cr.
  • Current Price ₹ 411
  • High / Low ₹ 730 / 407
  • Stock P/E 10.7
  • Book Value ₹ 436
  • Dividend Yield 2.22 %
  • ROCE 12.9 %
  • ROE 11.7 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Stock is trading at 0.94 times its book value

Cons

  • The company has delivered a poor sales growth of 9.49% over past five years.
  • Dividend payout has been low at 10.2% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022
5,600 5,895 6,158 5,925 6,483 6,365 6,002 5,702 5,942 6,002 5,809 6,236 5,739
4,460 4,688 4,862 4,679 5,071 5,011 4,735 4,502 4,766 4,993 4,839 5,303 4,950
Operating Profit 1,140 1,207 1,297 1,245 1,412 1,354 1,266 1,200 1,176 1,009 970 933 790
OPM % 20% 20% 21% 21% 22% 21% 21% 21% 20% 17% 17% 15% 14%
8 18 45 116 54 2,947 79 110 97 100 -114 41 57
Interest 41 37 32 21 16 19 18 13 10 16 9 15 25
Depreciation 243 250 232 256 257 277 266 280 294 299 254 280 298
Profit before tax 864 938 1,078 1,084 1,193 4,005 1,061 1,018 968 794 594 679 523
Tax % 26% 25% 21% 28% 32% 26% 24% 24% 28% 24% 3% 23% 22%
Net Profit 640 705 849 783 807 2,948 801 770 697 604 576 520 410
EPS in Rs 10.92 12.04 14.50 13.36 13.79 50.31 13.68 13.14 11.90 10.32 9.84 8.88 6.99
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 TTM
4,368 4,615 5,842 8,089 12,103 13,772 14,910 16,463 19,564 23,099 24,775 23,455 23,787
3,405 4,050 4,965 5,951 9,524 10,579 11,469 12,691 15,612 18,249 19,497 19,100 20,085
Operating Profit 963 565 877 2,137 2,579 3,193 3,441 3,772 3,952 4,849 5,278 4,356 3,702
OPM % 22% 12% 15% 26% 21% 23% 23% 23% 20% 21% 21% 19% 16%
61 -300 12 18 81 200 115 105 70 166 3,195 192 84
Interest 65 277 267 310 160 257 67 78 263 305 74 49 65
Depreciation 172 201 249 313 333 392 428 558 668 967 1,055 1,127 1,130
Profit before tax 788 -213 374 1,533 2,168 2,744 3,061 3,241 3,091 3,743 7,344 3,373 2,590
Tax % 29% 42% 22% 24% 28% 26% 25% 25% 24% 24% 27% 22%
Net Profit 563 -124 291 1,169 1,571 2,024 2,301 2,423 2,364 2,844 5,334 2,647 2,111
EPS in Rs 9.68 -2.12 5.05 20.12 26.98 34.61 39.29 41.36 40.36 48.56 91.05 45.20 36.03
Dividend Payout % 10% -24% 15% 7% 8% 7% 6% 6% 6% 6% 4% 20%
Compounded Sales Growth
10 Years: 18%
5 Years: 9%
3 Years: 6%
TTM: -1%
Compounded Profit Growth
10 Years: 31%
5 Years: 3%
3 Years: 4%
TTM: -29%
Stock Price CAGR
10 Years: 16%
5 Years: -7%
3 Years: -4%
1 Year: -39%
Return on Equity
10 Years: 20%
5 Years: 17%
3 Years: 16%
Last Year: 12%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Sep 2022
29 29 29 29 29 59 59 59 59 59 59 59 59
Reserves 2,416 2,311 2,577 3,721 5,127 7,229 9,313 11,622 13,832 16,766 21,871 24,517 25,469
2,414 3,096 3,435 3,769 4,451 5,041 3,364 4,770 6,967 5,826 5,339 2,851 4,501
1,009 798 1,232 1,970 3,303 3,568 3,464 4,492 5,414 6,113 6,147 6,211 7,138
Total Liabilities 5,868 6,234 7,273 9,490 12,910 15,896 16,200 20,942 26,271 28,765 33,416 33,638 37,167
1,739 2,195 2,639 2,722 3,706 4,180 4,834 6,521 8,475 9,396 9,374 10,532 11,616
CWIP 657 645 219 310 420 848 1,458 1,583 1,668 1,986 3,062 3,747 3,666
Investments 39 39 22 20 20 123 246 312 360 555 591 997 1,543
3,433 3,355 4,393 6,439 8,765 10,745 9,662 12,527 15,768 16,827 20,390 18,362 20,343
Total Assets 5,868 6,234 7,273 9,490 12,910 15,896 16,200 20,942 26,271 28,765 33,416 33,638 37,167

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
335 326 275 646 1,237 1,420 3,279 1,955 1,651 4,381 3,329 5,016
-603 -563 -246 -819 -1,017 -1,446 -1,787 -1,927 -2,904 -1,563 597 -3,211
407 119 108 118 93 365 -1,915 864 1,919 -1,947 -1,365 -2,969
Net Cash Flow 139 -118 137 -55 313 340 -424 892 666 871 2,561 -1,164

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Debtor Days 103 98 100 119 107 122 68 68 64 68 52 62
Inventory Days 244 224 235 240 239 240 246 317 304 289 333 272
Days Payable 130 96 118 137 136 146 122 128 107 97 103 97
Cash Conversion Cycle 217 226 217 222 210 217 191 257 260 260 282 237
Working Capital Days 134 148 171 162 126 141 122 139 148 120 124 120
ROCE % 20% 8% 11% 27% 27% 27% 25% 23% 18% 19% 18% 13%

Shareholding Pattern

Numbers in percentages

1 recently
Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022
52.01 52.01 52.01 51.94 51.94 51.83 51.83 51.83 51.83 51.83 51.84 51.84
22.26 22.63 23.01 24.99 24.37 23.70 21.71 21.37 20.83 20.71 21.41 22.31
12.56 12.56 13.67 12.61 13.24 14.66 15.52 16.49 17.47 17.30 16.56 14.90
13.16 12.80 11.31 10.47 10.45 9.80 10.93 10.31 9.86 10.15 10.20 10.96

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls